1. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American Urological Association. Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015; 193:1572–1580. DOI:
10.1016/j.juro.2015.01.087. PMID:
25623739.
Article
2. Danforth DN. Danforth's obstetrics and gynecology. 10 ed. Lippincott Williams & Wilkins;2008. p. 890–891.
3. Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010; 75:526–532. 532.e1–532.e18. DOI:
10.1016/j.urology.2009.06.096. PMID:
20035977.
Article
4. Nazarudheen S, Dey S, Kandhwal K, Arora R, Reyar S, Khuroo AH, et al. Combining benefits of an adrenergic and a muscarinic blocker in a single formulation–A pharmacokinetic evaluation. Regul Toxicol Pharmacol. 2013; 67:226–231. DOI:
10.1016/j.yrtph.2013.07.015. PMID:
23933032.
5. Jasek W, editor. Austria-Codex. 62nd ed. Vienna: Österreichischer Apothekerverlag;2007. p. 8659–8662. (in German).
7. Uchida T, Krauwinkel WJ, Mulder H, Smulders RA. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol. 2004; 58:4–7. PMID:
15206986.
Article